These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15202722)

  • 1. CCR1 antagonists for the treatment of autoimmune diseases.
    Gladue RP; Zwillich SH; Clucas AT; Brown MF
    Curr Opin Investig Drugs; 2004 May; 5(5):499-504. PubMed ID: 15202722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical potential of chemokine receptor antagonists.
    Ribeiro S; Horuk R
    Pharmacol Ther; 2005 Jul; 107(1):44-58. PubMed ID: 15894378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BX-471 Berlex.
    Elices MJ
    Curr Opin Investig Drugs; 2002 Jun; 3(6):865-9. PubMed ID: 12137405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases.
    Szekanecz Z; Koch AE; Tak PP
    Neth J Med; 2011 Sep; 69(9):356-66. PubMed ID: 21978977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR1 antagonists in clinical development.
    Pease JE; Horuk R
    Expert Opin Investig Drugs; 2005 Jul; 14(7):785-96. PubMed ID: 16022568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the chemokine system for multiple sclerosis treatment.
    Glabinsk AR; Ransohoff RM
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1712-9. PubMed ID: 11892933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components.
    Chen X; Oppenheim JJ; Howard OM
    Cell Mol Immunol; 2004 Oct; 1(5):336-42. PubMed ID: 16285892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.
    Szczuciński A; Losy J
    Acta Neurol Scand; 2007 Mar; 115(3):137-46. PubMed ID: 17295707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
    Carter PH; Tebben AJ
    Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine receptors: attractive targets for drug discovery.
    Godessart N
    Ann N Y Acad Sci; 2005 Jun; 1051():647-57. PubMed ID: 16127005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug discovery and chemokine receptor antagonists: eppur si muove!
    Terricabras E; Benjamim C; Godessart N
    Autoimmun Rev; 2004 Nov; 3(7-8):550-6. PubMed ID: 15546804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice.
    Liu W; Nakamura H; Shioji K; Tanito M; Oka S; Ahsan MK; Son A; Ishii Y; Kishimoto C; Yodoi J
    Circulation; 2004 Sep; 110(10):1276-83. PubMed ID: 15337697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis.
    Haringman JJ; Oostendorp RL; Tak PP
    Expert Opin Emerg Drugs; 2005 May; 10(2):299-310. PubMed ID: 15934868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.
    Carter PH; Hynes J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1609-18. PubMed ID: 20858032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR1 chemokine receptor antagonist.
    Saeki T; Naya A
    Curr Pharm Des; 2003; 9(15):1201-8. PubMed ID: 12769747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation.
    Futamatsu H; Suzuki J; Koga N; Adachi S; Kosuge H; Maejima Y; Haga T; Hirao K; Horuk R; Isobe M
    J Mol Cell Cardiol; 2006 Jun; 40(6):853-61. PubMed ID: 16698032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the chemokine network in renal inflammation.
    Eis V; Vielhauer V; Anders HJ
    Arch Immunol Ther Exp (Warsz); 2004; 52(3):164-72. PubMed ID: 15247883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of chemokine signaling in patients with multiple sclerosis.
    Zipp F; Hartung HP; Hillert J; Schimrigk S; Trebst C; Stangel M; Infante-Duarte C; Jakobs P; Wolf C; Sandbrink R; Pohl C; Filippi M;
    Neurology; 2006 Nov; 67(10):1880-3. PubMed ID: 17130431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments.
    Galimberti D; Bresolin N; Scarpini E
    Expert Rev Neurother; 2004 May; 4(3):439-53. PubMed ID: 15853541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
    Xie YF; Lake K; Ligsay K; Komandla M; Sircar I; Nagarajan G; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Dines K; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3367-72. PubMed ID: 17446072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.